Imipenem cilastatin adverse reactions: Difference between revisions
(Created page with "__NOTOC__ {{imipenem cilastatin}} {{CMG}} ==Adverse Reactions== ===Adults=== PRIMAXIN I.V. is generally well tolerated. Many of the 1,723 patients treated in clinical trial...") |
|||
| Line 48: | Line 48: | ||
{| | {| | ||
|- | |- | ||
|[[|thumb|400px|left]] | |[[Imipenem Cilastatin 5.jpg|thumb|400px|left]] | ||
|- | |- | ||
|} | |} | ||
| Line 56: | Line 56: | ||
{| | {| | ||
|- | |- | ||
|[[|thumb|400px|left]] | |[[Imipenem Cilastatin 6.jpg|thumb|400px|left]] | ||
|- | |- | ||
|} | |} | ||
| Line 62: | Line 62: | ||
{| | {| | ||
|- | |- | ||
|[[|thumb|400px|left]] | |[[Imipenem Cilastatin 7.jpg|thumb|400px|left]] | ||
|- | |- | ||
|} | |} | ||
| Line 68: | Line 68: | ||
{| | {| | ||
|- | |- | ||
|[[|thumb|400px|left]] | |[[Imipenem Cilastatin 8.jpg|thumb|400px|left]] | ||
|- | |- | ||
|} | |} | ||
Examination of published literature and spontaneous adverse event reports suggested a similar spectrum of adverse events in adult and pediatric patients.<ref>{{Cite web | last = | first = |title =http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050587s065,050630s028lbl.pdf | url =http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050587s065,050630s028lbl.pdf | publisher =|date = | accessdate = }}</ref> | Examination of published literature and spontaneous adverse event reports suggested a similar spectrum of adverse events in adult and pediatric patients.<ref>{{Cite web | last = | first = |title =http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050587s065,050630s028lbl.pdf | url =http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050587s065,050630s028lbl.pdf | publisher =|date = | accessdate = }}</ref> | ||
==References== | ==References== | ||
Revision as of 21:04, 26 December 2013
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Adverse Reactions
Adults
PRIMAXIN I.V. is generally well tolerated. Many of the 1,723 patients treated in clinical trials were severely ill and had multiple background diseases and physiological impairments, making it difficult to determine causal relationship of adverse experiences to therapy with PRIMAXIN I.V.
Local Adverse Reactions
Adverse local clinical reactions that were reported as possibly, probably, or definitely related to therapy with PRIMAXIN I.V. were:
Phlebitis/thrombophlebitis — 3.1%
Pain at the injection site — 0.7%
Erythema at the injection site — 0.4%
Vein induration — 0.2%
Infused vein infection — 0.1%
Systemic Adverse Reactions
The most frequently reported systemic adverse clinical reactions that were reported as possibly, probably, or definitely related to PRIMAXIN I.V. were nausea (2.0%), diarrhea (1.8%), vomiting (1.5%), rash (0.9%), fever (0.5%), hypotension (0.4%), seizures (0.4%) (see PRECAUTIONS), dizziness (0.3%), pruritus (0.3%), urticaria (0.2%), somnolence (0.2%).
Additional adverse systemic clinical reactions reported as possibly, probably, or definitely drug related occurring in less than 0.2% of the patients or reported since the drug was marketed are listed within each body system in order of decreasing severity: Gastrointestinal — pseudomembranous colitis (the onset of pseudomembranous colitis symptoms may occur during or after antibacterial treatment, see WARNINGS), hemorrhagic colitis, hepatitis (including fulminant hepatitis), hepatic failure, jaundice, gastroenteritis, abdominal pain, glossitis, tongue papillar hypertrophy, staining of the teeth and/or tongue, heartburn, pharyngeal pain, increased salivation; Hematologic — pancytopenia, bone marrow depression, thrombocytopenia, neutropenia, leukopenia, hemolytic anemia; CNS — encephalopathy, tremor, confusion, myoclonus, paresthesia, vertigo, headache, psychic disturbances including hallucinations; Special Senses — hearing loss, tinnitus, taste perversion; Respiratory — chest discomfort, dyspnea, hyperventilation, thoracic spine pain; Cardiovascular — palpitations, tachycardia; Skin — Stevens-Johnson syndrome, toxic epidermal necrolysis, erythema multiforme, angioneurotic edema, flushing, cyanosis, hyperhidrosis, skin texture changes, candidiasis, pruritus vulvae; Body as a whole — polyarthralgia, asthenia/weakness, drug fever; Renal — acute renal failure, oliguria/anuria, polyuria, urine discoloration. The role of PRIMAXIN I.V. in changes in renal function is difficult to assess, since factors predisposing to pre-renal azotemia or to impaired renal function usually have been present.
Adverse Laboratory Changes
Adverse laboratory changes without regard to drug relationship that were reported during clinical trials or reported since the drug was marketed were:
Hepatic: Increased ALT (SGPT), AST (SGOT), alkaline phosphatase, bilirubin, and LDH
Hemic: Increased eosinophils, positive Coombs test, increased WBC, increased platelets, decreased hemoglobin and hematocrit, agranulocytosis, increased monocytes, abnormal prothrombin time, increased lymphocytes, increased basophils
Electrolytes: Decreased serum sodium, increased potassium, increased chloride
Renal: Increased BUN, creatinine
Urinalysis: Presence of urine protein, urine red blood cells, urine white blood cells, urine casts, urine bilirubin, and urine urobilinogen.
Pediatric Patients
In studies of 178 pediatric patients ≥3 months of age, the following adverse events were noted:
| thumb|400px|left |
In studies of 135 patients (newborn to 3 months of age), the following adverse events were noted:
| thumb|400px|left |
| thumb|400px|left |
| thumb|400px|left |
Examination of published literature and spontaneous adverse event reports suggested a similar spectrum of adverse events in adult and pediatric patients.[1]
References
- ↑ "http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050587s065,050630s028lbl.pdf" (PDF). External link in
|title=(help)
Adapted from the FDA Package Insert.